Skip to Content

Sodium hyaluronate Pregnancy and Breastfeeding Warnings

Sodium hyaluronate is also known as: Durolane, Euflexxa, Gelsyn-3, Hyalgan, Supartz, Supartz FX

Medically reviewed by Drugs.com. Last updated on Mar 27, 2018.

Sodium hyaluronate Pregnancy Warnings

It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Safety has not been established.

US FDA pregnancy category: Not assigned.

Risk Summary: Animal studies have failed to reveal evidence of fertility impairment or teratogenicity.

See references

Sodium hyaluronate Breastfeeding Warnings

Safety has not been established.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments:
-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Hyalgan (hyaluronidate sodium)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  2. "Product Information. Supartz (sodium hyaluronate)." Smith and Nephew Wound Management Division, Largo, FL.

References for breastfeeding information

  1. "Product Information. Hyalgan (hyaluronidate sodium)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  2. "Product Information. Supartz (sodium hyaluronate)." Smith and Nephew Wound Management Division, Largo, FL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide